# Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department

> **NCT07726069** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **University of Illinois at Chicago** · enrollment: 100 (estimated)

## Conditions studied

- Cannabinoid Hyperemesis Syndrome

## Interventions

- **DRUG:** Haloperidol

## Key facts

- **NCT ID:** NCT07726069
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11
- **Primary completion:** 2028-01
- **Final completion:** 2028-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07726069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07726069, "Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07726069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*